Cellular therapy for sickle cell disease

about

A prospective study of the association between sickle cell disease and hepatobiliary effects in Bahrain A Review of Bunyamwera, Batai, and Ngari Viruses: Understudied Orthobunyaviruses With Potential One Health Implications.

P2860

Q41347905-64406719-4CC7-4AF8-8E3E-0E376551B151 Q54225511-783E90F3-C7CF-4A17-8A3D-AF7691AF555B

P2860

Cellular therapy for sickle cell disease

Item

http://www.wikidata.org/entity/Q38898163

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Cellular therapy for sickle cell disease

@en

type

Item

label

Cellular therapy for sickle cell disease

@en

prefLabel

Cellular therapy for sickle cell disease

@en

P1476

Cellular therapy for sickle cell disease

@en

P2093

Allistair Abraham

http://www.w3.org/2001/XMLSchema#string

Catherine M Bollard

http://www.w3.org/2001/XMLSchema#string

David A Jacobsohn

http://www.w3.org/2001/XMLSchema#string

P2860

CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes

Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines.

Improved survival of children and adolescents with sickle cell disease.

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Hydroxyurea-inducible SAR1 gene acts through the Giα/JNK/Jun pathway to regulate γ-globin expression

Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions.

A humanized monoclonal antibody specific for invariant Natural Killer T (iNKT) cells for in vivo depletion

P304

1360-1369

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCYT.2016.06.011

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27421743

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

5067194

http://www.w3.org/2001/XMLSchema#string

Cellular therapy for sickle cell disease

about

P2860

P2860

Cellular therapy for sickle cell disease

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932